BioStem Technologies — Third Quarter 2026 Earnings Summary

BioStem Technologies reported third-quarter 2026 net revenue of $7.6 million, with hospital revenue rising sequentially to $6.8 million. The company raised its full-year 2026 revenue guidance to a range of $28 million to $29 million, up from the previous outlook. In-house production of Neox and Clarix products is scheduled to commence in the first half of 2027, marking progress toward vertical integration. The company also closed a private placement generating approximately $3 million in gross proceeds and established a $40 million committed equity facility.